Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2005 6
2006 1
2007 2
2008 3
2009 3
2010 4
2011 1
2012 2
2013 2
2014 3
2015 5
2016 6
2017 4
2018 5
2019 6
2020 7
2021 7
2022 14
2023 12
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean curtin conrad (13 results)?
The cGAS-STING pathway drives type I IFN immunopathology in COVID-19.
Domizio JD, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K, Nass T, Guenova E, Schaller M, Conrad C, Goepfert C, de Leval L, Garnier CV, Berezowska S, Dubois A, Gilliet M, Ablasser A. Domizio JD, et al. Among authors: conrad c. Nature. 2022 Mar;603(7899):145-151. doi: 10.1038/s41586-022-04421-w. Epub 2022 Jan 19. Nature. 2022. PMID: 35045565 Free PMC article.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. Among authors: conrad c. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Biomarkers of disease progression in people with psoriasis: a scoping review.
Ramessur R, Corbett M, Marshall D, Acencio ML, Barbosa IA, Dand N, Di Meglio P, Haddad S, Jensen AHM, Koopmann W, Mahil SK, Ostaszewski M, Rahmatulla S, Rastrick J, Saklatvala J, Weidinger S, Wright K, Eyerich K, Ndlovu M, Barker JN, Skov L, Conrad C, Smith CH; BIOMAP consortium. Ramessur R, et al. Among authors: conrad c. Br J Dermatol. 2022 Oct;187(4):481-493. doi: 10.1111/bjd.21627. Epub 2022 Jul 11. Br J Dermatol. 2022. PMID: 35482474 Free PMC article. Review.
TYK-ing all the boxes in psoriasis.
Schlapbach C, Conrad C. Schlapbach C, et al. Among authors: conrad c. J Allergy Clin Immunol. 2022 Jun;149(6):1936-1939. doi: 10.1016/j.jaci.2022.03.014. Epub 2022 Mar 24. J Allergy Clin Immunol. 2022. PMID: 35341877 Free article. No abstract available.
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, Del Alcázar-Viladomiu E, Rull EV, Llamas-Velasco M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A. Torres T, et al. Among authors: conrad c. Am J Clin Dermatol. 2022 Nov;23(6):891-904. doi: 10.1007/s40257-022-00722-y. Epub 2022 Aug 17. Am J Clin Dermatol. 2022. PMID: 35976568
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Daudén E, Conrad C, Mendes-Bastos P, Ferreira P, Leite L, Lu JD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas-Velasco M, Del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung J, Nogueira M, Chiricozzi A. Torres T, et al. Among authors: conrad c. Am J Clin Dermatol. 2021 Jul;22(4):567-579. doi: 10.1007/s40257-021-00598-4. Epub 2021 Mar 30. Am J Clin Dermatol. 2021. PMID: 33786754
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Thaçi D, Vender R, de Rie MA, Conrad C, Pariser DM, Strober B, Vanvoorden V, Wang M, Madden C, de Cuyper D, Kimball AB. Thaçi D, et al. Among authors: conrad c. Br J Dermatol. 2023 Jan 23;188(1):22-31. doi: 10.1093/bjd/ljac021. Br J Dermatol. 2023. PMID: 36689515 Clinical Trial.
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
Iversen L, Conrad C, Eidsmo L, Costanzo A, Narbutt J, Pinter A, Kingo K, Rivera Diaz R, Kolbinger F, Nanna M, Frueh JA, Jagiello P. Iversen L, et al. Among authors: conrad c. J Eur Acad Dermatol Venereol. 2023 May;37(5):1004-1016. doi: 10.1111/jdv.18846. Epub 2023 Jan 27. J Eur Acad Dermatol Venereol. 2023. PMID: 36606536 Clinical Trial.
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Mrowietz U, Barker J, Conrad C, Jullien D, Gisondi P, Flower A, Reddy J, Paris M, Picard H, Jardon S, Augustin M. Mrowietz U, et al. Among authors: conrad c. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):348-355. doi: 10.1111/jdv.18689. Epub 2022 Nov 14. J Eur Acad Dermatol Venereol. 2023. PMID: 36300769 Clinical Trial.
90 results